Kenichi Yasunari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kenichi Yasunari has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Junichi Yoshikawa
4 shared publicationsTakanori Watanabe
Osaka City Univ, Grad Sch Med, Dept Med & Cardiol, Osaka 5458585, Japan
4 shared publicationsKensaku Maeda
3 shared publicationsMunehiro Nakamura
3 shared publicationsAkira Asada
Department of General Medicine and Cardiology, Graduate School of Medicine, Osaka City University, Osaka, Japan
2 shared publicationsK Maeda
2 shared publications
Latest Publications
- 1 June 2006
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 19 (6) , 573-578
Anxiety-Induced Plasma Norepinephrine Augmentation Increases Reactive Oxygen Species Formation by Monocytes in Essential Hypertension
An association between anxiety and depression and increased blood pressure (BP) and cardiovascular disease risk has not been firmly established. We examined the hypothesis that anxiety and depression lead to increased plasma catecholamines and to production of reactive oxygen species (ROS) by mononuclear cells (MNC) in hypertensive individuals. We also studied the role of BP in this effect. In Protocol 1, a cross-sectional study was performed in 146 hypertensive patients to evaluate whether anxiety and depression affect BP and ROS formation by MNC through increasing plasma catecholamines. In Protocol 2, a 6-month randomized controlled trial using a subtherapeutic dose of the alpha(1)-adrenergic receptor antagonist doxazosin (1 mg/day) versus placebo in 86 patients with essential hypertension was performed to determine whether the increase in ROS formation by MNC was independent of BP. In Protocol 1, a significant relationship was observed between the following: trait anxiety and plasma norepinephrine (r = 0.32, P < .01); plasma norepinephrine and ROS formation by MNC (r = 0.36, P < .01); and plasma norepinephrine and systolic, diastolic, and mean BP (r = 0.17, P = .04; r = 0.26, P = .02; r = 0.23, P < .01, respectively). In Protocol 2, subtherapeutic doxazosin treatment (1 mg/day) had no significant effect on BP. However doxazosin significantly decreased ROS formation by MNC compared with placebo (P < .01). Trait anxiety may increase plasma norepinephrine and increase ROS formation by MNC independent of BP in hypertensive patients.
- 1 June 2006
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 19 (6) , 573-578
Anxiety-Induced Plasma Norepinephrine Augmentation Increases Reactive Oxygen Species Formation by Monocytes in Essential Hypertension
An association between anxiety and depression and increased blood pressure (BP) and cardiovascular disease risk has not been firmly established. We examined the hypothesis that anxiety and depression lead to increased plasma catecholamines and to production of reactive oxygen species (ROS) by mononuclear cells (MNC) in hypertensive individuals. We also studied the role of BP in this effect. In Protocol 1, a cross-sectional study was performed in 146 hypertensive patients to evaluate whether anxiety and depression affect BP and ROS formation by MNC through increasing plasma catecholamines. In Protocol 2, a 6-month randomized controlled trial using a subtherapeutic dose of the alpha(1)-adrenergic receptor antagonist doxazosin (1 mg/day) versus placebo in 86 patients with essential hypertension was performed to determine whether the increase in ROS formation by MNC was independent of BP. In Protocol 1, a significant relationship was observed between the following: trait anxiety and plasma norepinephrine (r = 0.32, P < .01); plasma norepinephrine and ROS formation by MNC (r = 0.36, P < .01); and plasma norepinephrine and systolic, diastolic, and mean BP (r = 0.17, P = .04; r = 0.26, P = .02; r = 0.23, P < .01, respectively). In Protocol 2, subtherapeutic doxazosin treatment (1 mg/day) had no significant effect on BP. However doxazosin significantly decreased ROS formation by MNC compared with placebo (P < .01). Trait anxiety may increase plasma norepinephrine and increase ROS formation by MNC independent of BP in hypertensive patients.
- 1 May 2006
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 2 (2) , 147-151
Antioxidative Actions of Carvedilol in the Treatment of Hypertension
It has been suggested that carvedilol may provide greater benefit than traditional β-blockers in the treatment of chronic heart failure and hypertension because of its antioxidant effects. We have shown that carvedilol inhibits pressure-induced increase in oxidative stress in human coronary smooth muscle cells in culture. We have also shown that carvedilol inhibits oxidative stress of polymorphonuclear cells (PMNs) in spontaneously hypertensive rats independently of blood pressure. We have examined the effect of carvedilol on reactive oxygen species (ROS) formation by PMNs and mononuclear cells (MNCs) in patients with essential hypertension. ROS formation by PMNs and MNCs in hypertensive patients were significantly increased compared with those in normotensive controls. Carvedilol 20mg significantly decreased ROS formation by PMNs and in MNCs. These findings suggest that carvedilol inhibits ROS formation by PMNs and in MNCs. Thus, in vitro, in vivo and human data of antioxidative actions of carvedilol in the treatment of hypertension will be shown.
- 1 May 2006
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 2 (2) , 147-151
Antioxidative Actions of Carvedilol in the Treatment of Hypertension
It has been suggested that carvedilol may provide greater benefit than traditional β-blockers in the treatment of chronic heart failure and hypertension because of its antioxidant effects. We have shown that carvedilol inhibits pressure-induced increase in oxidative stress in human coronary smooth muscle cells in culture. We have also shown that carvedilol inhibits oxidative stress of polymorphonuclear cells (PMNs) in spontaneously hypertensive rats independently of blood pressure. We have examined the effect of carvedilol on reactive oxygen species (ROS) formation by PMNs and mononuclear cells (MNCs) in patients with essential hypertension. ROS formation by PMNs and MNCs in hypertensive patients were significantly increased compared with those in normotensive controls. Carvedilol 20mg significantly decreased ROS formation by PMNs and in MNCs. These findings suggest that carvedilol inhibits ROS formation by PMNs and in MNCs. Thus, in vitro, in vivo and human data of antioxidative actions of carvedilol in the treatment of hypertension will be shown.
- Open Access
- 9 February 2006
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 20 (5) , 336-340
Carotid artery intima-media thickness and reactive oxygen species formation by monocytes in hypertensive patients
Carotid artery intima-media thickness (IMT) is a widely accepted index for assessing atherosclerosis, and is known to be a risk indicator for cardiovascular and cerebrovascular events. Oxidative stress and inflammation are also known to play critical roles in the pathogenesis of vascular events. We studied the association between IMT and inflammatory markers, such as oxidative stress in polymorphonuclear leukocytes (PMNs) and mononuclear cells (MNCs) in 156 patients with essential hypertension. Reactive oxygen species (ROS) formation by PMNs and MNCs was measured by gated flow cytometry. CRP and traditional risk factors, such as age, gender, body mass index, hemoglobin A1c, and total cholesterol were also measured. The subjects were divided into a plaque group (max-IMT1.1 mm, n=40), and a nonplaque group (max-IMTn=116). ROS formation by MNCs was significantly increased in the plaque group when compared with the nonplaque group (Pr=0.407, Pr=0.216, P=0.0029) or hemoglobinA1c (r=0.158, P=0.0270) or age (r=0.157, P=0.0447). No significant correlation was observed between IMT and ROS formation by PMNs. These results suggest that carotid artery IMT may be affected by increased ROS formation by MNCs, and that increased ROS formation by MNCs may be related to the development of atherosclerosis. We propose that ROS formation by MNCs is a marker for prediction of carotid atherosclerosis.
- 9 February 2006
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 20 (5) , 336-340
Open AccessCarotid artery intima-media thickness and reactive oxygen species formation by monocytes in hypertensive patients
Carotid artery intima-media thickness (IMT) is a widely accepted index for assessing atherosclerosis, and is known to be a risk indicator for cardiovascular and cerebrovascular events. Oxidative stress and inflammation are also known to play critical roles in the pathogenesis of vascular events. We studied the association between IMT and inflammatory markers, such as oxidative stress in polymorphonuclear leukocytes (PMNs) and mononuclear cells (MNCs) in 156 patients with essential hypertension. Reactive oxygen species (ROS) formation by PMNs and MNCs was measured by gated flow cytometry. CRP and traditional risk factors, such as age, gender, body mass index, hemoglobin A1c, and total cholesterol were also measured. The subjects were divided into a plaque group (max-IMT1.1 mm, n=40), and a nonplaque group (max-IMTn=116). ROS formation by MNCs was significantly increased in the plaque group when compared with the nonplaque group (Pr=0.407, Pr=0.216, P=0.0029) or hemoglobinA1c (r=0.158, P=0.0270) or age (r=0.157, P=0.0447). No significant correlation was observed between IMT and ROS formation by PMNs. These results suggest that carotid artery IMT may be affected by increased ROS formation by MNCs, and that increased ROS formation by MNCs may be related to the development of atherosclerosis. We propose that ROS formation by MNCs is a marker for prediction of carotid atherosclerosis.
- 1 January 2005
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry-Cardiovascular & Hematological Agents
- Vol. 3 (1) , 61-67
Left Ventricular Hypertrophy and Angiotensin II Receptor Blocking Agents
Angiotensin II plays a significant role in cell growth and proliferation in model systems and in humans. Numerous studies have shown that left ventricular hypertrophy (LVH) increases the risk of coronary heart disease, congestive heart failure, stroke or transient ischemic attack; all-cause deaths, and sudden death. The use of angiotensinconverting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) has provided beneficial effects on LVH regression and on cardiac remodeling in the presence of hypertension and heart failure. The new class of ARBs appears to provide cardioprotective effects that are similar to those of the ACE inhibitors. Most of the beneficial effects provided by these agents appear to be related to a more complete blockade of the angiotensin II type 1 (AT1) receptor. However, costimulation of the angiotensin II type 2 (AT2) receptor appears to increase nitric oxide and thus causes some bradykinin-like effects. Evidence for the role of angiotensin II in promoting LVH as well as abnormal regulation of the angiotensin II signal transduction pathways in model systems and in humans has been reviewed. Secondly, the mechanisms for the beneficial effects of angiotensin II receptor blockers studied in model systems and in humans, including possible involvement in the formation of reactive oxygen species by mononuclear cells, are presented. Finally, results from large-scale interventions such as the Losartan Intervention For Endpoint reduction (LIFE) study, as well as an overview of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial involving the use of ARB in highrisk patients, are presented.
- 1 January 2005
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry-Cardiovascular & Hematological Agents
- Vol. 3 (1) , 61-67
Left Ventricular Hypertrophy and Angiotensin II Receptor Blocking Agents
Angiotensin II plays a significant role in cell growth and proliferation in model systems and in humans. Numerous studies have shown that left ventricular hypertrophy (LVH) increases the risk of coronary heart disease, congestive heart failure, stroke or transient ischemic attack; all-cause deaths, and sudden death. The use of angiotensinconverting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) has provided beneficial effects on LVH regression and on cardiac remodeling in the presence of hypertension and heart failure. The new class of ARBs appears to provide cardioprotective effects that are similar to those of the ACE inhibitors. Most of the beneficial effects provided by these agents appear to be related to a more complete blockade of the angiotensin II type 1 (AT1) receptor. However, costimulation of the angiotensin II type 2 (AT2) receptor appears to increase nitric oxide and thus causes some bradykinin-like effects. Evidence for the role of angiotensin II in promoting LVH as well as abnormal regulation of the angiotensin II signal transduction pathways in model systems and in humans has been reviewed. Secondly, the mechanisms for the beneficial effects of angiotensin II receptor blockers studied in model systems and in humans, including possible involvement in the formation of reactive oxygen species by mononuclear cells, are presented. Finally, results from large-scale interventions such as the Losartan Intervention For Endpoint reduction (LIFE) study, as well as an overview of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial involving the use of ARB in highrisk patients, are presented.
- 1 January 2005
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 28 (2) , 107-112
Benidipine, a Long-Acting Calcium Channel Blocker, Inhibits Oxidative Stress in Polymorphonuclear Cells in Patients with Essential Hypertension
Hypertension Research, official publication of the Japanese Society of Hypertension, publishes papers reporting original clinical and experimental research in the field of hypertension and related cardiovascular diseases.
- 1 January 2005
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 28 (2) , 107-112
Benidipine, a Long-Acting Calcium Channel Blocker, Inhibits Oxidative Stress in Polymorphonuclear Cells in Patients with Essential Hypertension
Hypertension Research, official publication of the Japanese Society of Hypertension, publishes papers reporting original clinical and experimental research in the field of hypertension and related cardiovascular diseases.
- Open Access
- 1 September 2004
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 22 (3) , 189-198
Pharmacological and Clinical Studies with Temocapril, an Angiotensin Converting Enzyme Inhibitor that is Excreted in the Bile
Temocapril is an angiotensin converting enzyme inhibitor (ACEI), a prodrug with a thiazepine ring. Its active form, temocaprilat, is slightly more potent than enalaprilat in inhibiting ACE isolated from rabbit lung. The inhibitory potency of temocaprilat on isolated rat aorta is 3 times that of enalaprilat. Temocapril is excreted in the bile and urine and can be used in patients with renal insufficiency. It reduces blood pressure without causing any significant change in heart rate or cardiac output. Temocapril has been reported to improve endothelial dysfunction in vitro by suppressing increased oxidative stress. In vivo it improves reactive hyperemia in patients with essential hypertension. It has been reported to prevent coronary vascular remodeling in vivo by suppressing local ACE and increased oxidative stress. In humans temocapril has been found to improve insulin resistance partly by increasing adiponectin levels. Cardiac remodeling was improved by temocapril not only in experiment animals but also in humans. It improves renal function and decreases urinary albumin excretion in diabetics as well as in hypertensive patients. Temocapril is currently marketed only in Japan. Considering its beneficial effects and unique pharmaco‐kinetics, temocapril, is likely to be introduced in other countries as well.
- 1 September 2004
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 22 (3) , 189-198
Open AccessPharmacological and Clinical Studies with Temocapril, an Angiotensin Converting Enzyme Inhibitor that is Excreted in the Bile
Temocapril is an angiotensin converting enzyme inhibitor (ACEI), a prodrug with a thiazepine ring. Its active form, temocaprilat, is slightly more potent than enalaprilat in inhibiting ACE isolated from rabbit lung. The inhibitory potency of temocaprilat on isolated rat aorta is 3 times that of enalaprilat. Temocapril is excreted in the bile and urine and can be used in patients with renal insufficiency. It reduces blood pressure without causing any significant change in heart rate or cardiac output. Temocapril has been reported to improve endothelial dysfunction in vitro by suppressing increased oxidative stress. In vivo it improves reactive hyperemia in patients with essential hypertension. It has been reported to prevent coronary vascular remodeling in vivo by suppressing local ACE and increased oxidative stress. In humans temocapril has been found to improve insulin resistance partly by increasing adiponectin levels. Cardiac remodeling was improved by temocapril not only in experiment animals but also in humans. It improves renal function and decreases urinary albumin excretion in diabetics as well as in hypertensive patients. Temocapril is currently marketed only in Japan. Considering its beneficial effects and unique pharmaco‐kinetics, temocapril, is likely to be introduced in other countries as well.
- 1 August 1996
- Published by Wolters Kluwer Health in Hypertension
- Vol. 28 (2) , 159-168
Possible Involvement of Phospholipase D and Protein Kinase C in Vascular Growth Induced by Elevated Glucose Concentration
Hyperglycemia is believed to be a major cause of diabetic vascular complications. To elucidate the effect of hyperglycemia on vascular response, we studied hyperproliferation, hypertrophy, and the natriuretic peptide response of vascular smooth muscle cells under high-glucose conditions. We observed that cells cultured in high glucose (22.2 mmol/L) showed hyperproliferation and hypertrophy and that natriuretic peptide receptor responses were suppressed compared with cells cultured in normal glucose (5.6 mmol/L). We also examined phospholipase D and protein kinase C activities and found that in high-glucose conditions such activities are higher than in cells cultured in normal glucose. The activation of phospholipase D was not prevented by coincubation with 1 μmol/L protein kinase C(19-36), a specific protein kinase C inhibitor, but the activation of protein kinase C was. Protein kinase C(19-36) also markedly attenuated vascular hyperproliferation and hypertrophy as well as glucose-induced suppression of natriuretic peptide receptor response. These results show that hyperglycemia may be linked to vascular hyperproliferation, hypertrophy, and a suppressed natriuretic peptide receptor response, which are caused by increased phospholipase D and protein kinase C activities.
- 1 August 1996
- Published by Wolters Kluwer Health in Hypertension
- Vol. 28 (2) , 159-168
Possible Involvement of Phospholipase D and Protein Kinase C in Vascular Growth Induced by Elevated Glucose Concentration
Hyperglycemia is believed to be a major cause of diabetic vascular complications. To elucidate the effect of hyperglycemia on vascular response, we studied hyperproliferation, hypertrophy, and the natriuretic peptide response of vascular smooth muscle cells under high-glucose conditions. We observed that cells cultured in high glucose (22.2 mmol/L) showed hyperproliferation and hypertrophy and that natriuretic peptide receptor responses were suppressed compared with cells cultured in normal glucose (5.6 mmol/L). We also examined phospholipase D and protein kinase C activities and found that in high-glucose conditions such activities are higher than in cells cultured in normal glucose. The activation of phospholipase D was not prevented by coincubation with 1 μmol/L protein kinase C(19-36), a specific protein kinase C inhibitor, but the activation of protein kinase C was. Protein kinase C(19-36) also markedly attenuated vascular hyperproliferation and hypertrophy as well as glucose-induced suppression of natriuretic peptide receptor response. These results show that hyperglycemia may be linked to vascular hyperproliferation, hypertrophy, and a suppressed natriuretic peptide receptor response, which are caused by increased phospholipase D and protein kinase C activities.